Know Cancer

or
forgot password

    • cancer clinical trials in nashville, TN

    • Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
    Tennessee Clinical Research Center
    Nashville, Tennessee 37221
    Psoriasis, Psoriatic Arthritis
    Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
    Reserach Site
    Nashville, Tennessee
    Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics,, Tumour Response.
    Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Multiple Myeloma
    Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
    Vanderbilt University
    Nashville, Tennessee 37232-6305
    High Risk Acute Myeloid Leukemia
    Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    SCRI
    Nashville, Tennessee 37203
    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
    A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
    Sara Cannon Research Institute
    Nashville, Tennessee 37203
    Relapsed or Refractory Lymphoid Malignancies
    Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
    Call for Information (Investigational Site 0033)
    Nashville, Tennessee 37232
    Malignant Melanoma
    A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Pharmacokinetics of ASP9853, Non-hematologic Malignancies
    Forces During Skull Base Surgery
    Vanderbilt University Skull Base Center
    Nashville, Tennessee 37212
    Skull Base, Pituitary, Robotics, Endonasal Surgery, Sinus Surgery
    Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
    A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
    Sarah Cannon Research Institute SCRI 3
    Nashville, Tennessee 37203
    PIK3CA Mutated Advanced Solid Tumors,, PIK3CA Amplified Advanced Solid Tumors
    A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
    Vanderbilt University Medical Center Dept of Oncology
    Nashville, Tennessee 37232
    Medulloblastoma
    Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
    Sarah Cannon Research Institute SCRI SC
    Nashville, Tennessee 37203
    Colorectal Cancer
    Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
    Urology Associates, P.C.
    Nashville, Tennessee 37209
    Prostate Cancer
    Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
    Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2516
    Cutaneous T-Cell Lymphoma
    A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
    Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232
    Squamous Cell Carcinoma of the Head and Neck
    Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Low to Intermediate-1 MDS
    A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
    Tennessee Clinical Research Center
    Nashville, Tennessee 37221
    Actinic Keratosis
    Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Multiple Myeloma, Lymphoma
    Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
    Vanderbilt Children's Hospital
    Nashville, Tennessee 37232-6310
    Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
    Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.
    Tennessee Oncology Dept. of Centennial Medical

    Trial Locations
    Tennessee Oncology Dept. of Centennial Medical
    Vanderbilt Univeristy Ingram Cancer Center (10)
    CML
    Early Diagnosis of Pulmonary Nodules
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Precancerous Conditions, Carcinoma
    Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
    Nashville Medical Research Institute
    Nashville, Tennessee 37205
    Ulcerative Colitis
    A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
    Tennessee Oncology
    Nashville, Tennessee 37203
    Renal Cell Carcinoma
    Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
    TG Therapeutics Trial Site
    Nashville, Tennessee 37203
    Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma
    ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
    Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Ovarian Cancer
    Promoting Adherence to Lymphedema Self-care
    Vanderbilt Univeristy School Of Nursing
    Nashville, Tennessee 37240
    Lymphedema Self-care
    Phase 1/2 Dose-Escalation, Safety, PK & PD Study of BVD-523, an ERK 1/2 Inhibitor, in Patients With Advanced Malignancies
    Sarah Cannon Research Institute Hospital at Vanderbilt
    Nashville, Tennessee 37203
    Advanced Solid Tumors
    Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
    Sarah Cannon Research Institute Sarah Cannon Research (SC)
    Nashville, Tennessee 37203
    Chronic Myelogenous Leukemia
    A Twelve Week Safety and Efficacy Study in Rosacea
    Tennessee Clinical Research Center
    Nashville, Tennessee 37221
    Papulopustular Rosacea
    DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules
    Middle Tennessee Research Institute (Vanderbilt University)
    Nashville, Tennessee
    Lung Cancer
    BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers
    Vanderbilt University
    Nashville, Tennessee 37232-6305
    Tobacco Use Disorder, Smoking
    Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
    Safety and Tolerability Study in Solid Tumors
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer
    ADAM-Afatinib Diarrhea Assessment and Management
    1200.167.01005 Boehringer Ingelheim Investigational Site
    Nashville, Tennessee
    Carcinoma, Non-Small-Cell Lung
    Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Acute Myelogenous Leukemia
    A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

    Nashville, Tennessee 37203-1632
    Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
    Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
    Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37232
    Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
    An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

    Nashville, Tennessee 37203-1632
    Metastatic Cancer, Metastatic Pancreatic Cancer
    Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Breast Cancer
    Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
    Vanderbilt
    Nashville, Tennessee 37212
    HER2-mutant Non-Small Cell Lung Cancer
    Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Multiple Myeloma
    An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

    Nashville, Tennessee 37203-1632
    Relapsed or Refractory Mantle Cell Lymphoma
    Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Unresectable or Metastatic Melanoma
    Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
    Sarah Cannon Research Institute
    Nashville, Tennessee 37203
    Advanced Solid Tumors (Excluding Breast Cancer)
    Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
    Sarah Cannon Cancer Center
    Nashville, Tennessee 37203
    Myelodysplastic Syndrome
    Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

    Nashville, Tennessee 37203-1632
    KIF5B-RET-Positive Adenocarcinoma of the Lung
    Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838
    Osteosarcoma, Paget's Disease
    A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma

    Nashville, Tennessee 37203-1632
    Indolent Non-Hodgkin Lymphoma
    Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

    Nashville, Tennessee 37203-1632
    Advanced, Androgen Recpetor Positive Triple Negative Breast Cancer
    Risk Factors for Adult-Onset Brain Tumors
    Vanderbilt University Medical Center, Department of Neurological Surgery
    Nashville, Tennessee 37232
    Brain Neoplasm, Primary, Brain Neoplasms, Malignant, Brain Neoplasms, Benign
    Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
    Sarah Cannon
    Nashville, Tennessee 37203
    B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma,, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma